Scholarlink

<p>The role of SLC26A3 in the sensitivity to oxaliplatin, a widely used chemotherapy drug for colorectal cancer (CRC), remains unclear. This study aimed to explore the association between SLC26A3 expression and oxaliplatin sensitivity. Total 240 differentially expressed mRNAs were identified, with 124 downregulated and 116 upregulated in oxaliplatin-resistant CRC. WGCNA identified a module significantly associated with resistance. GO and KEGG analyses revealed enrichment in fatty acid metabolic processes and organic anion transmembrane transporter activity. PCA and feature gene selection identified a 15-gene signature, with SLC26A3 highlighted by machine learning models as a key discriminator of chemosensitivity. Immunohistochemical staining and survival analysis indicated that higher SLC26A3 expression correlated with better survival outcomes. Additionally, a significant negative correlation between SLC26A3 and AKT1 was observed, suggesting that while SLC26A3 may enhance oxaliplatin sensitivity, its effect may be overshadowed by other factors in resistant cells. SLC26A3 may play a crucial role in oxaliplatin sensitivity in CRC. The identified gene signature could potentially serve as a biomarker for predicting chemosensitivity to oxaliplatin.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Up-regulation of SLC26A3 enhances oxaliplatin sensitivity in colorectal cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月28日

查看全文
  • Junyang Wang,
  • Shaodong Tang,
  • Min Zhang,
  • Songhe Li,
  • Dacheng Wen

摘要

The role of SLC26A3 in the sensitivity to oxaliplatin, a widely used chemotherapy drug for colorectal cancer (CRC), remains unclear. This study aimed to explore the association between SLC26A3 expression and oxaliplatin sensitivity. Total 240 differentially expressed mRNAs were identified, with 124 downregulated and 116 upregulated in oxaliplatin-resistant CRC. WGCNA identified a module significantly associated with resistance. GO and KEGG analyses revealed enrichment in fatty acid metabolic processes and organic anion transmembrane transporter activity. PCA and feature gene selection identified a 15-gene signature, with SLC26A3 highlighted by machine learning models as a key discriminator of chemosensitivity. Immunohistochemical staining and survival analysis indicated that higher SLC26A3 expression correlated with better survival outcomes. Additionally, a significant negative correlation between SLC26A3 and AKT1 was observed, suggesting that while SLC26A3 may enhance oxaliplatin sensitivity, its effect may be overshadowed by other factors in resistant cells. SLC26A3 may play a crucial role in oxaliplatin sensitivity in CRC. The identified gene signature could potentially serve as a biomarker for predicting chemosensitivity to oxaliplatin.